Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04964440 · ClinicalTrials.gov registry record
Redo AF Sub Study (of the Pure EP 2.0 Main Study)
A clinical trial of Atrial Fibrillation Recurrent, sponsored by BioSig Technologies.
- Completed
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT04964440: Completed study of Atrial Fibrillation Recurrent, sponsored by BioSig Technologies.
NCT04964440 is a study of Atrial Fibrillation Recurrent that has completed, run by BioSig Technologies. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04964440, a study of Atrial Fibrillation Recurrent, has completed, sponsored by BioSig Technologies.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a sub study of the Pure EP 2.0 trial. In a redo atrial fibrillation population, this study is designed to collect pulmonary vein signals pre and post ablation therapy, along with other non-pulmonary vein signals of interest during a redo ablation procedure. These signals are later evaluated for clinical relevance and impact on the procedure.
Primary Outcome
The signals of interest will undergo a homogenization process to remove all identifiers of the system used. At a later time, a blinded electrophysiologist reviewer will evaluate the signals for clinical relevance and procedural impact from both systems using the same Blinded Signal Assessment Form. The Blinded Assessment Form results will be compared to both each other and what was done at the procedure.
Conditions Studied
Interventions
- DEVICE Pure-EP
Study Locations (1)
Texas
- St. David's Medical Center - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-03-03 |
| Est. Completion | 2022-01-29 |
What the finished NCT04964440 record still lists
NCT04964440 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 1 condition, with Atrial Fibrillation Recurrent appearing as the primary indexed condition, and to 1 intervention - of which Pure-EP is the first listed.
NCT04964440 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04964440 about?
NCT04964440 is a clinical study titled "Redo AF Sub Study (of the Pure EP 2.0 Main Study)". This study is a sub study of the Pure EP 2.0 trial. In a redo atrial fibrillation population, this study is designed to collect pulmonary vein signals pre and post ablation therapy, along with other non-pulmonary vein signals of interest during a redo ablation procedure. These signals are later eval...
What is the current status of trial NCT04964440?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2021-03-03. Estimated completion is 2022-01-29.
What conditions does trial NCT04964440 study?
This clinical trial studies the following conditions: Atrial Fibrillation Recurrent.
What interventions are being tested in trial NCT04964440?
The interventions under investigation include: Pure-EP (DEVICE).
Who is sponsoring clinical trial NCT04964440?
This trial is sponsored by BioSig Technologies, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04964440 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI